The charts of 311 patients receiving theophylline (T) and 289 patients receiving ipratropium bromide (IB) for COPD were reviewed to determine the total costs and cost-effectiveness of these 2 agents in 3 different health-care settings.
A direct cost-accounting method assessed cost, and a Markov decision-analysis model calculated cost-effectiveness.
Costs to treat toxic effects were greater for T versus IB.
The types and incidences of toxic effects, by drug, were similar among the three centers.
Overall costs for T were $121.40 per patient per therapy-month versus $84.56 per patient per therapy-month for IB, as determined by the cost-accounting method.
Mots-clés Pascal : Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Economie santé, Traitement, Homme, Etude comparative, Chimiothérapie, Bronchodilatateur, Analyse coût efficacité
Mots-clés Pascal anglais : Respiratory disease, Obstructive pulmonary disease, Health economy, Treatment, Human, Comparative study, Chemotherapy, Bronchodilator, Cost efficiency analysis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0437241
Code Inist : 002B02D. Création : 199406.